AARDVARK THERAPEUTICS INC (AARD:NASDAQ)
$3.91 0.27 (7.4176%)
Analysed AARDVARK THERAPEUTICS INC (AARD:NASDAQ) News Sources
A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial
05-03-2026
yahoo.com
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
23-03-2026
yahoo.com
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings
29-03-2026
yahoo.com
Discover 3 Promising Penny Stocks With Market Caps Over $100M
17-04-2026
yahoo.com
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07-05-2026
yahoo.com
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
14-05-2026
yahoo.com
FDA hold puts Aardvark Prader-Willi drug in limbo
15-05-2026
biopharmadive.com
Top Midday Decliners
15-05-2026
yahoo.com
Sector Update: Healthcare Stocks Decline Late Afternoon
15-05-2026
yahoo.com
Several Insiders Invested In Aardvark Therapeutics Flagging Positive News
28-05-2026
yahoo.com
What is the current price of AARDVARK THERAPEUTICS INC (AARD:NASDAQ)?
The current price of AARDVARK THERAPEUTICS INC (AARD:NASDAQ) is $3.91.
AARDVARK THERAPEUTICS INC (AARD:NASDAQ) absolute price change since previous trading day?
The absolute price change of AARDVARK THERAPEUTICS INC (AARD:NASDAQ) since the previous trading day is $0.27.
AARDVARK THERAPEUTICS INC (AARD:NASDAQ) percentage price change since previous trading day?
The percentage price change of AARDVARK THERAPEUTICS INC (AARD:NASDAQ) since the previous trading day is 7.4176%.
What is the most recent average sentiment score for AARDVARK THERAPEUTICS INC (AARD:NASDAQ)?
The most recent average sentiment score for AARDVARK THERAPEUTICS INC (AARD:NASDAQ) is 57 out of 100.
What is the most recent average sentiment for AARDVARK THERAPEUTICS INC (AARD:NASDAQ)?
The most recent sentiment for AARDVARK THERAPEUTICS INC (AARD:NASDAQ) is .
SEC-8K** Filing Available For AARDVARK THERAPEUTICS INC (AARD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.